Patent Description:
Generally, most drugs are administered orally. However, when orally administered, some drugs, particularly protein and peptide drugs, cannot be effectively adsorbed due to severe decomposition in the gastrointestinal tract, poor absorption by the intestinal membranes, and/or interruption of first pass metabolism in the liver.

Another drug delivery technique is parenteral administration using a standard syringe or catheter. However, syringe injection causes needle phobia, substantial pain, and local damage to the skin in many patients. Collection of body fluids such as blood for diagnostic purposes causes similar anxieties. In addition, syringe injection is not ideal for continuous drug delivery or for continuous diagnosis.

Yet another drug delivery technique is transdermal delivery that commonly relies on drug diffusion across the skin. However, this method is not widely used due to insufficient permeability of the skin to many drugs. The outermost layer of the skin, that is, the homy layer is a primary barrier to transdermal drug penetration. Once a drug reaches the dermis (under the epithelium), the drug rapidly spreads into deep tissue layers and other parts of the body through blood circulation. <CIT>, <CIT>, <CIT>, <CIT>, <CIT>, <CIT> describe multi-step fabrication methods for microneedle arrays and the respective devices comprising nucleic acid.

In an attempt to improve protein drug delivery through the skin, chemical enhancers, iontophoresis, electroporation, ultrasonication, and thermal elements have been used to supplement drug delivery. However, these techniques are not appropriate for certain drug forms and often do not provide therapeutic delivery. In addition, these techniques sometimes cause unwanted skin reactions and are impractical to control drug delivery over several hours or several days.

Embodiments of the present invention provide a nucleic acid film fabrication method and nucleic acid film-based drug administration device which can be applied to a transdermal delivery technology relying on drug diffusion across the human skin so as to improve drug penetration into the skin while preventing skin problems.

In accordance with one aspect of the present invention, there is provided a nucleic acid film fabrication method comprising:a mixing step (S1) in which <NUM> parts by weight to <NUM> parts by weight of a nucleic acid (<NUM> b) is added in powder form to <NUM> parts by weight of distilled water or deionized water (la) to prepare a mixed solution;a stirring step (S2) in which the mixed solution is stirred;a mixed solution application step (S3) in which the mixed solution is applied to a mold (<NUM>) corresponding in shape to a final product of a nucleic acid film (<NUM>);a drying step (S4) in which the mixed solution applied to the mold (<NUM>) is dried to be formed into the nucleic acid film (<NUM>); anda film acquisition step (S7) in which the nucleic acid film (<NUM>) is separated from the mold (<NUM>) after the drying step (S4).

The nucleic acid film fabrication method may further include an oblique angle deposition step in which a coating layer is formed on the one surface of the nucleic acid film such that a tip of the protrusion is exposed, after the drying step.

The nucleic acid film fabrication method may further include an oblique angle deposition step in which a coating layer is formed on the mold excluding a bottom end of the groove, before the mixed solution application step.

The nucleic acid film fabrication method may further include an oblique angle deposition step in which a coating layer is formed on the other surface of the nucleic acid film such that a portion of the coating layer corresponding to the protrusion is open, after the drying step.

The nucleic acid film fabrication method may further include: a finishing application step in which a finishing liquid is applied to cover the coating layer; and a finishing drying step in which the finishing liquid is dried to be formed into a finishing layer, after the oblique angle deposition step.

The nucleic acid film fabrication method may further include a mold preparation step in which the mold is machined to correspond in shape to the final product of the nucleic acid film before the mixed solution application step; and a surface treatment step in a surface of the mold is treated to be hydrophobic before the mixed solution application step.

In the mixing step, <NUM> part by weight to <NUM> parts by weight of a drug may be further added in liquid or capsule form to the mixed solution.

The nucleic acid may be extracted from at least one of by-products of marine food processing and by-products of plant food processing.

In accordance with another aspect of the present invention, there is provided a nucleic acid film-based drug administration device including: a nucleic acid film configured to contact the human skin and fabricated by the nucleic acid film fabrication method set forth above; a finishing film stacked on the nucleic acid film; and a drug filling a space between the nucleic acid film and the finishing film.

The nucleic acid film-based drug administration device may further include: a boundary film stacked between the nucleic acid film and the finishing film; and a decomposing liquid filling a space between the boundary film and the finishing film and comprising distilled water or deionized water, wherein the finishing film may include a perforation needle protruding therefrom toward the boundary film and configured to perforate the boundary film, and the drug may fill a space between the nucleic acid film and the boundary film.

In accordance with a further aspect of the present invention, there is provided a nucleic acid film-based drug administration device including a nucleic acid film fabricated by the nucleic acid film fabrication method in which, in the mixing step, <NUM> part by weight to <NUM> parts by weight of a drug is further added in liquid, powder, or capsule form to the mixed solution.

The nucleic acid film-based drug administration device may further include: a boundary film stacked on the nucleic acid film; a finishing film stacked on the boundary film and including a perforation needle protruding therefrom toward the boundary film, the perforation needle being configured to perforate the boundary film; and a decomposing liquid filling a space between the boundary film and the finishing film and comprising distilled water or deionized water.

The nucleic acid film may include a microneedle protruding from one surface thereof toward a human skin.

The nucleic acid film may include a buffer groove formed on the other surface thereof to correspond to the microneedle.

The nucleic acid film-based drug administration device may further include a coating layer formed on the one surface of the nucleic acid film such that a tip of the microneedle is exposed.

The nucleic acid film-based drug administration device may further include a coating layer formed on the other surface of the nucleic acid film such that a portion of the coating layer corresponding to the microneedle is open.

The nucleic acid film may include a drug delivery portion protruding from one surface thereof toward the human skin, wherein the drug delivery portion may have a drug injection hole formed therethrough to allow the drug to be discharged through the drug injection hole.

The nucleic acid film-based drug administration device may further include: a coating layer formed on the one surface of the nucleic acid film such that a tip of the drug delivery portion is exposed.

The nucleic acid film-based drug administration device may further include a coating layer formed on the other surface of the nucleic acid film such that a portion of the coating layer corresponding to the drug injection hole is open.

The nucleic acid film-based drug administration device may further include a protective film detachably coupled to the one surface of the nucleic acid film such that the drug injection hole is open or closed.

The nucleic acid film fabrication method and nucleic acid film-based drug administration device according to the present invention can be applied to transdermal delivery technology relying on drug diffusion across the human skin, thereby improving drug penetration into the skin while preventing skin problems.

In addition, a microneedle, a buffer groove, and a drug delivery portion having a drug injection hole <NUM> formed therethrough can be easily formed on a nucleic acid film and the nucleic acid film can have a uniform thickness.

Further, according to the present invention, the nucleic acid film can retain the shape thereof for a long time.

Moreover, according to the present invention, it is possible to prevent intrusion of foreign matter into the nucleic acid film while improving decomposition of the nucleic acid film.

Furthermore, a decomposing liquid can be stably supplied to the nucleic acid film, thereby enabling stable drug delivery.

In addition, depending on the form of drug delivery, the nucleic acid film can be patterned in various ways and the dosage of a drug can be adjusted according to the pattern of the nucleic acid film.

Further, according to the present invention, leakage of a drug through the drug injection hole and intrusion of foreign matter into the drug can be prevented while protecting the nucleic acid film.

It should be understood that the present invention is not limited to the following embodiments and may be embodied in different ways.

In the drawings, portions irrelevant to the description will be omitted for clarity. Like components will be denoted by like reference numerals throughout the specification.

It will be understood that when an element is referred to as being "connected to" another element, it can be directly connected to the other element, or intervening elements may also be present. In addition, it will be understood that the terms "includes", "comprises", "including" and/or "comprising," when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups.

It will be understood that when an element such as a layer, film, region or substrate is referred to as being placed "above"/"below" or "on"/"under" another element, it can be directly placed on the other element, or intervening layer(s) may also be present. In addition, spatially relative terms, such as "above," "upper (portion)," "upper surface," and the like may be understood as meaning "below," "lower (portion)," "lower surface," and the like according to a reference orientation. In other words, the expressions of spatial orientations are to be construed as indicating relative orientations instead of absolute orientations (that is, orientations with respect to the direction of gravity).

Now, a nucleic acid film fabrication method according to a first embodiment of the present invention will be described. <FIG> is a flowchart of a nucleic acid film fabrication method according to a first embodiment of the present invention, <FIG> is a view illustrating each process in the nucleic acid film fabrication method according to the first embodiment, <FIG> is a sectional view of a mold used in the nucleic acid film fabrication method according to the first embodiment, <FIG> is an image of a microneedle of a nucleic acid film fabricated by the nucleic acid film fabrication method according to the first embodiment, and <FIG> is a view showing a process of directly forming a coating layer on a nucleic acid film in the nucleic acid film fabrication method according to the first embodiment.

Here, <FIG> is a view of a first mold <NUM> formed with a needle groove <NUM>, <FIG> is a view of a second mold <NUM> formed with a buffer formation groove <NUM> and a needle groove <NUM>, and <FIG> is a view of a third mold <NUM> formed with a delivery groove <NUM> and an injection protrusion <NUM>, wherein the first to third molds are used as a mold <NUM> according to the present invention.

In addition, the top of <FIG> shows an oblique angle deposition process for forming a coating layer <NUM> on a final product of a nucleic acid film <NUM> and the bottom of <FIG> shows a state in which the coating layer <NUM> is secured to the final product of the nucleic acid film <NUM>.

Referring to <FIG>, in the nucleic acid film fabrication method according to the first embodiment of the invention, the nucleic acid film <NUM> is fabricated using a powdery nucleic acid 1b.

Here, the nucleic acid 1b may be extracted from at least one of by-products of marine food processing and by-products of plant food processing.

Examples of the by-products of marine food processing may include salmon testes, salmon skins, pollack testes, crab carapaces, squid inks, and mixtures thereof.

Examples of the by-products of plant food processing may include yeasts of cereal crops or seed grains, such as brewer's yeast, rice yeast, and barley yeast, and mixtures thereof.

Specifically, the nucleic acid 1b may include a salmon nucleic acid extracted from salmon, among the by-products of marine food processing. When the nucleic acid 1b includes a salmon nucleic acid, poly deoxy ribo nucleotide (PDRN) in the salmon nucleic acid can help treatment of wounds and scars and skin regeneration without addition of specific drugs. In addition, the salmon nucleic acid can help to quickly heal skin wounds caused by a microneedle after removing a drug administration device from the human skin.

The nucleic acid film fabrication method according to the first embodiment includes a mixing step (S1), a stirring step (S2), a mixed solution application step (S3), and a drying step (S4).

In the mixing step (S1), a mixed solution is prepared by adding the nucleic acid 1b to an aqueous solution 1a in a mixing container <NUM>.

The mixing container <NUM> is reduced in width toward the bottom thereof, such that the aqueous solution 1a and the nucleic acid 1b can be stably stirred. Here, the aqueous solution 1a may include distilled water or deionized water and the nucleic acid 1b may be provided in powder form.

According to the invention the mixed solution is prepared by adding <NUM> parts by weight to <NUM> parts by weight of the nucleic acid 1b to <NUM> parts by weight of the aqueous solution 1a (distilled water or deionized water). Here, the amount of the nucleic acid 1b may be adjusted according to the thickness of the final product of the nucleic acid film <NUM>.

By way of one example, the nucleic acid 1b may be present in an amount of <NUM> parts by weight to <NUM> parts by weight relative to <NUM> parts by weight of the aqueous solution 1a. By way of another example, the nucleic acid 1b may be present in an amount of <NUM> part by weight to <NUM> parts by weight relative to <NUM> parts by weight of the aqueous solution 1a. By way of a further example, the nucleic acid 1b may be present in an amount of <NUM> parts by weight to <NUM> parts by weight relative to <NUM> parts by weight of the aqueous solution 1a. In other words, the amount of the nucleic acid 1b may be changed in multiples of <NUM> parts by weight within a range of <NUM> parts by weight to <NUM> parts by weight.

If the amount of the nucleic acid 1b is outside the predetermined range set forth above, the final product of the nucleic acid film <NUM> can have holes, cannot have a film shape, or can have cracks. In addition, when the final product of the nucleic acid film <NUM> is in use, it takes a long time for the final product of the nucleic acid film <NUM> to be decomposed, causing a delay in penetration of a drug into the skin.

Conversely, when the amount of the nucleic acid 1b falls within the predetermined range, the final product of the nucleic acid film <NUM> can stably have a film shape without any cracks and can be decomposed in a predetermined period of time using a decomposing liquid <NUM> described below, thereby improving penetration of a drug into the skin.

In order to prevent the aqueous solution 1a and the nucleic acid 1b from being contaminated during mixing of the aqueous solution 1a and the nucleic acid lb, the mixing container <NUM> may be washed in advance with deionized water, isopropyl alcohol, acetone, and deionized water, in that order.

Particularly, in the mixing step (S1), <NUM> part by weight to <NUM> parts by weight of a drug <NUM> is further added in liquid, powder, or capsule form to the mixed solution. In other words, the amount of the drug <NUM> may be changed in multiples of <NUM> parts by weight within a range of <NUM> part by weight to <NUM> parts by weight relative to <NUM> parts by weight of the mixed solution. In addition, the amount of the drug <NUM> may be adjusted according to a desired dosage of the drug into the human skin.

In this way, since both the nucleic acid 1b and the drug <NUM> are mixed with the aqueous solution 1a, it is possible to obtain a final product of the nucleic acid film <NUM> in which the nucleic acid 1b is integrated with the drug <NUM>.

In the stirring step (S2), the mixed solution obtained through the mixing step (S1) is stirred. In the stirring step (S2), the mixing container <NUM> is sealed with a sealant <NUM> such as Parafilm, followed by stirring the mixed solution in a stirring unit <NUM>.

For example, the stirring unit <NUM> may be a magnetic stirrer, wherein a magnet <NUM> of the magnetic stirrer may be immersed in the mixed solution in the mixing container <NUM> after being washed with deionized water. It should be understood that the mixing container may be sealed with the sealant <NUM> after immersing the magnet <NUM> in the mixed solution.

In the stirring step (S2), the mixed solution is rotated only in one direction to retain a conical shape, such that the nucleic acid 1b is uniformly mixed in the mixed solution.

In the stirring step (S2), stirring of the mixed solution is performed at <NUM> rpm to <NUM> rpm for <NUM> to <NUM> hours. For example, in the stirring step (S2), the mixed solution may be stirred at <NUM> rpm for <NUM> to <NUM> hours, followed by further stirring at <NUM> rpm for <NUM> to <NUM> hours.

In addition, in the stirring step (S2), the mixed solution may be allowed to stand for a predetermined period of time in a space shielded from UV light and sunlight so as to stabilize the mixed phase of the mixed solution.

In the mixed solution application step (S3), the mixed solution passing through the stirring step (S2) is applied to the mold <NUM>. Here, the mold <NUM> may have a shape corresponding to the shape of the final product of the nucleic acid film <NUM>.

The amount of the mixed solution applied to the mold <NUM> may be adjusted according to the size and thickness of the final product of the nucleic acid film <NUM>.

In the mixed solution application step (S3), after applying the mixed solution to the mold <NUM>, vacuum treatment may be performed for about <NUM> hour (for example, <NUM> to <NUM> minutes) so as to keep the mixed solution applied to the mold <NUM> in a stable manner and to promote drying of the mixed solution.

In the drying step (S4), the mixed solution applied to the mold <NUM> is dried to be formed into the nucleic acid film <NUM>. In the drying step (S4), the mold <NUM> having the mixed solution applied thereto is dried in a drying unit <NUM> at a predetermined temperature for a predetermined period of time.

The drying step (S4) may include drying the mold <NUM> having the mixed solution applied thereto in the drying unit <NUM> at a temperature of <NUM> to <NUM> for <NUM> to <NUM> days. For example, the drying step (S4) may include drying the mold <NUM> having the mixed solution applied thereto in the drying unit <NUM> at a temperature of <NUM> to <NUM> for <NUM> to <NUM> days. If the temperature of the drying unit <NUM> is below the lower limit of the temperature range set forth above, the time required for drying can be increased, whereas, if the temperature of the drying unit <NUM> exceeds the upper limit of the temperature range set forth above, the final product of the nucleic acid film <NUM> can have defects such as cracks.

When the drying step (S4) is performed at the predetermined temperature for the predetermined period of time as set forth above, the final product of the nucleic acid film <NUM> can have a stable structure.

In the drying step (S4), bubbles may be removed from the mixed solution dried in the mold <NUM> using a pipetting unit <NUM>.

The nucleic acid film fabrication method according to the first embodiment may further include at least one of a surface treatment step (S5), a mold preparation step (S6), a film acquisition step (S7), and an oblique angle deposition step (S8).

In the surface treatment step (S5), a surface of the mold <NUM> is treated to be hydrophobic prior to the mixed solution application step (S3). In the surface treatment step (S5), the surface of the mold <NUM> may be treated to be hydrophobic using a surface treatment unit <NUM> generating oxygen plasma. In the surface treatment step (S5), the mold <NUM> subjected to surface-treatment using the surface treatment unit <NUM> may be dried at room temperature for about <NUM> day.

Through the surface treatment step (S5), a hydrophilic surface of the mold <NUM> can be turned hydrophobic, while the mixed solution can be applied to the mold <NUM> to a uniform thickness.

In addition, due to hydrophobicity of the surface of the mold <NUM>, a virtual membrane is formed between the mixed solution and the mold <NUM>, thereby allowing the final product of the nucleic acid film <NUM> to be safely separated from the mold <NUM>.

In the mold preparation step S6, the mold <NUM> is subjected to machining to correspond in shape to the final product of the nucleic acid film <NUM>, before the mixed solution application step (S3), more specifically, before the surface treatment step (S5).

By way of one example, in the mold preparation step (S6), the mold <NUM> may be machined to have a flat surface.

By way of another example, in the mold preparation step (S6), the mold <NUM> may be machined to have a needle groove <NUM>. Such a mold <NUM> will be referred to as a first mold <NUM>. That is, the first mold <NUM> has a needle groove <NUM> formed on a surface thereof to be tapered in a thickness direction thereof, as shown in <FIG>. Accordingly, the final product of the nucleic acid film <NUM> includes a microneedle <NUM> protruding therefrom.

By way of a further example, in the mold preparation step (S6), the mold <NUM> may be machined to have a buffer formation groove <NUM>. Such a mold <NUM> will be referred to as a second mold <NUM>. That is, the second mold <NUM> has a buffer formation groove <NUM> formed on a surface thereof, as shown in <FIG>, wherein the buffer formation groove corresponds to a portion of the final product of the nucleic acid film configured to receive the drug <NUM>. In addition, a needle groove <NUM> may be further formed on the buffer formation groove <NUM>. Accordingly, the final product of the nucleic acid film <NUM> includes a buffer groove <NUM> formed convex toward the human skin and a microneedle <NUM> protruding from an outer surface of the buffer groove <NUM> toward the human skin.

By way of yet another example, in the mold preparation step (S6), the mold <NUM> may be machined to have a delivery groove <NUM> and an injection protrusion <NUM> formed on the delivery groove <NUM>. Such a mold <NUM> will be referred to as a third mold <NUM>. That is, the third mold <NUM> has a delivery groove <NUM> formed on the surface thereof to be tapered in a thickness direction thereof and the injection protrusion <NUM> protruding from the delivery groove <NUM>. Accordingly, the final product of the nucleic acid film <NUM> includes a drug delivery portion <NUM> protruding from a surface thereof and a drug injection hole <NUM> passing through the drug delivery portion <NUM>.

In the film acquisition step (S7), the nucleic acid film <NUM> passing through the drying step (S4) is separated from the mold <NUM>. Through the film acquisition step S7, it is possible to obtain the nucleic acid film <NUM> having a predetermined thickness. Here, the nucleic acid film <NUM> may have a thickness of <NUM> nanometers to several hundred micrometers. For example, the nucleic acid film <NUM> may have a thickness of several hundred nanometers.

In the oblique angle deposition step (S8), a coating layer <NUM> is formed on the final product of the nucleic acid film <NUM>. The coating layer <NUM> may be formed of an inorganic or organic material which is not decomposed by the decomposing liquid <NUM> described below and is harmless to humans. For example, the coating layer <NUM> may contain a material such as gold, silver, etc. as a main ingredient. Through the oblique angle deposition step (S8), the nucleic acid film <NUM> can retain a shape thereof in a stable manner. Particularly, through the oblique angle deposition step (S8), the geometries of the microneedle <NUM>, the buffer groove <NUM>, and the drug delivery portion <NUM> protruding from the nucleic acid film <NUM> can be maintained for a long time, while the nucleic acid film <NUM> can remain flat or remain held against the human body for a long time.

The oblique angle deposition step (S8) is performed for the final product of the nucleic acid film <NUM> obtained by applying the mixed solution to the mold <NUM>, that is, the first mold <NUM>, the second mold <NUM>, or the third mold <NUM>, followed by the drying step (S4) or the film acquisition step (S7), as shown in <FIG> and <FIG>.

Here, the final product of the nucleic acid film <NUM> obtained through the drying step (S4) or the film acquisition step (S7) includes the microneedle <NUM> or the drug delivery portion <NUM> extending therefrom toward the human skin.

In the oblique angle deposition step (S8), the coating layer <NUM> may be formed to cover at least the microneedle <NUM> such that a tip of the microneedle <NUM> is exposed or may be formed to cover at least the drug delivery portion <NUM> such that a tip of the drug delivery portion <NUM> is exposed. Particularly, for the nucleic acid film <NUM> formed with the drug delivery portion <NUM>, the coating layer <NUM> is formed not to close the drug injection hole <NUM> described below.

In the oblique angle deposition step (S8), with the tip of the microneedle <NUM> covered with a first deposition aid member 15a, the coating layer <NUM> may be formed to cover at least the microneedle <NUM>. In addition, in the oblique angle deposition step S8, with the tip of the drug delivery portion <NUM> covered with the first deposition aid member 15a, the coating layer <NUM> may be formed to cover at least the drug delivery portion <NUM>. After formation of the coating layer <NUM> in the oblique angle deposition step (S8), the first deposition aid member 15a is removed from the nucleic acid film <NUM>.

Firstly, for a final product of the nucleic acid film <NUM> obtained using the first mold <NUM>, the phrase "the tip of the microneedle <NUM> or the tip of the drug delivery portion <NUM> is exposed" may mean that the coating layer <NUM> is formed on the final product of the nucleic acid film <NUM> in the following manner: The coating layer <NUM> may cover only the microneedle <NUM> excluding the tip of the microneedle <NUM>, may cover the microneedle <NUM> excluding the tip of the microneedle <NUM> and a portion of one surface of the nucleic acid film <NUM> on which the microneedle <NUM> is formed, or may cover the microneedle <NUM> excluding the tip of the microneedle <NUM> and the entirety of one surface of the nucleic acid film <NUM> on which the microneedle <NUM> is formed.

Secondly, for a final product of the nucleic acid film <NUM> obtained using the second mold <NUM>, the phrase "the tip of the microneedle <NUM> or the tip of the drug delivery portion <NUM> is exposed" may mean that the coating layer <NUM> is formed on the final nucleic acid film <NUM> in the following manner: The coating layer <NUM> may cover only an outer surface of the buffer groove <NUM>, may cover the outer surface of the buffer groove <NUM> and the microneedle <NUM> excluding the end of the microneedle <NUM>, may cover at least the outer surface of the buffer groove <NUM> and a portion of one surface of the nucleic acid film <NUM> on which the buffer groove <NUM> is formed, or may cover at least the outer surface of the buffer groove <NUM> and the entirety of one surface of the nucleic acid film <NUM> on which the buffer groove <NUM> is formed.

Thirdly, for a final nucleic acid film <NUM> obtained using the third mold <NUM>, the phrase "the tip of the microneedle <NUM> or the tip of the drug delivery portion <NUM> is exposed" may mean that the coating layer <NUM> is formed on the final nucleic acid film <NUM> in the following manner: The coating layer <NUM> may cover only the drug delivery portion <NUM> excluding the tip of the drug delivery portion <NUM>, may cover the drug delivery portion <NUM> excluding the tip of the drug delivery portion <NUM> and a portion of one surface of the nucleic acid film <NUM> on which the drug delivery portion <NUM> is formed, or may cover the drug delivery portion <NUM> excluding the end of drug delivery portion <NUM> and the entirety of one surface of the nucleic acid film <NUM> on which the drug delivery portion <NUM> is formed.

In this way, in the nucleic acid film fabrication method according to the first embodiment, the coating layer can be formed on the microneedle <NUM>, the buffer groove <NUM>, and the drug delivery portion <NUM> formed with the drug injection hole <NUM> of the final product of the nucleic acid film <NUM>.

In the oblique angle deposition step (S8), any typical method such as oblique angle deposition, partial plating, partial coating, or sputtering may be employed to exclude the tip of the microneedle <NUM> or the tip of the drug delivery portion <NUM> from being covered with the coating layer. In the nucleic acid film fabrication method according to the first embodiment, oblique angle deposition is employed to exclude the tip of the microneedle <NUM> or the tip of the drug delivery portion <NUM> from being covered with the coating layer. The oblique angle deposition step S8 includes a process of curing the coating layer <NUM>.

In this way, the coating layer <NUM> can be formed on the final product of the nucleic acid film <NUM> such that the tip of the microneedle <NUM> or the tip of the drug delivery portion <NUM> is exposed.

Next, a nucleic acid film fabrication method according to a second embodiment of the present invention will be described. <FIG> is a flowchart of the nucleic acid film fabrication method according to the second embodiment and <FIG> shows a process of forming a coating layer on a nucleic acid film using a mold formed with the coating layer in the nucleic acid film fabrication method according to the second embodiment.

Here, the top of <FIG> shows a coating layer <NUM> formed on a mold <NUM>, the middle of <FIG> shows a nucleic acid film <NUM> stacked on the mold <NUM> formed with the coating layer <NUM>, and the bottom of <FIG> shows the nucleic acid film <NUM> and the coating layer <NUM> removed from the mold <NUM>, wherein the coating layer <NUM> is secured to the nucleic acid film <NUM>.

Referring to <FIG> and <FIG>, the nucleic acid film fabrication method according to the second embodiment includes a mixing step (S1), a stirring step (S2), a mixed solution application step (S3), and a drying step (S4).

In addition, the nucleic acid film fabrication method according to the second embodiment may further include at least one of a surface treatment step (S5), a mold preparation step (S6), a film acquisition step (S7), and an oblique angle deposition step (S8).

With regard to the nucleic acid film fabrication method according to the second embodiment, the same components as those used in the nucleic acid film fabrication method according to the first embodiment will be denoted by the same reference numerals as in the first embodiment and description thereof will be omitted.

In the oblique angle deposition (S8) according to this embodiment, the coating layer <NUM> is secured to the nucleic acid film <NUM> after being formed on the mold <NUM>.

The oblique angle deposition step (S8) is performed on the first mold <NUM> or the second mold <NUM>, which is used as the mold <NUM> according to the present invention, prior to the mixed solution application step (S3). In other words, the oblique angle deposition step (S8) is performed on the first mold <NUM>, the second mold <NUM>, or the third mold <NUM>, as the mold <NUM>, after the surface treatment step (S5) and before the mixed solution application step (S3).

For example, in the mold preparation step (S6), a needle groove <NUM> tapered in a thickness direction thereof may be formed on the mold <NUM>.

In the oblique angle deposition (S8), the coating layer <NUM> is formed at at least an entrance of the needle groove <NUM> excluding a bottom end of the needle groove <NUM>.

By way of one example, with regard to the first mold <NUM>, the phrase "excluding a bottom end of the needle groove <NUM>" may mean that the coating layer <NUM> is formed on the first mold in the following manner: The coating layer <NUM> may be formed only at the entrance of the needle groove <NUM>, may be formed at the entrance of the needle groove <NUM> and on a portion of one surface of the mold <NUM> on which the needle groove <NUM> is formed, or may be formed at the entrance of the needle groove <NUM> and on the entirety of one surface of the mold <NUM> on which the needle groove <NUM> is formed.

By way of another example, with regard to the second mold <NUM>, the phrase "excluding a bottom end of the needle groove <NUM>" may mean that the coating layer <NUM> is formed on the second mold in the following manner: The coating layer <NUM> may also be formed on the buffer formation groove <NUM>. The coating layer <NUM> may be formed only on the buffer formation groove <NUM>, may be formed on the buffer formation groove <NUM> and at the entrance of the needle groove <NUM>, may be formed at least on the buffer formation groove <NUM> and on a portion of one surface of the mold <NUM> on which the buffer formation groove <NUM> is formed, or may be formed at least on the buffer formation groove <NUM> and on the entirety of one surface of the mold <NUM> on which the buffer formation groove <NUM> is formed.

By way of a further example, with regard to the third mold <NUM>, the phrase "excluding a bottom end of the needle groove <NUM>" may mean that the coating layer <NUM> is formed in the following manner: The coating layer <NUM> may also be formed on the delivery groove <NUM>. The coating layer <NUM> may be formed only on the delivery groove <NUM>, may be formed at least on the delivery groove <NUM> and on a portion of one surface of the mold <NUM> on which the delivery groove <NUM> is formed, or may be formed at least on the delivery groove <NUM> and on the entirety of one surface of the mold <NUM> on which the delivery groove <NUM> is formed. Here, the injection protrusion <NUM> is not involved in formation of the coating layer <NUM>.

Although not shown in the drawings, in the oblique angle deposition step S8, with the bottom end of the needle groove <NUM>, the bottom end of the buffer formation groove <NUM>, or the bottom end of the delivery groove <NUM> covered with a separate deposition aid member (not shown), the coating layer <NUM> may be formed at the entrance of the needle groove <NUM> or the delivery groove <NUM>, followed by removal of the deposition aid member.

In the oblique angle deposition step (S8), any typical method such as oblique angle deposition, partial plating, partial coating, or sputtering may be employed to exclude the bottom end of the needle groove <NUM>, the bottom end of the buffer formation groove <NUM>, or the bottom end of the delivery groove <NUM> from being covered with the coating layer. In the nucleic acid film fabrication method according to the second embodiment, oblique angle deposition is employed to form the coating layer <NUM>. The oblique angle deposition step (S8) includes a process of curing the coating layer <NUM>.

In the mixed solution application step (S3), the mixed solution is applied to the mold <NUM> while filling the needle groove <NUM>, and, in the drying step (S4), the coating layer <NUM> is integrated with a final product of the nucleic acid film <NUM>. Accordingly, in the film acquisition step (S7), the nucleic acid film <NUM> and the coating layer <NUM> integrated with each other are removed from the mold <NUM> at the same time.

In this way, the final product of the nucleic acid film <NUM> has the coating layer <NUM> formed thereon such that a tip of a microneedle <NUM> formed using the needle groove <NUM> is exposed.

Next, a nucleic acid film fabrication method according to a third embodiment of the present invention will be described. <FIG> is a flowchart of a nucleic acid film fabrication method according to a third embodiment of the present invention and <FIG> is a view illustrating a process of embedding a coating layer in a nucleic acid film in the nucleic acid film fabrication method according to the third embodiment of the present invention.

Here, the top of <FIG> shows a nucleic acid film <NUM> having a buffer groove <NUM> formed thereon, the upper middle of <FIG> shows a coating layer <NUM> stacked on the nucleic acid film <NUM> having the buffer groove <NUM> formed thereon, the lower middle of <FIG> shows a finishing layer <NUM> stacked on the nucleic acid film <NUM> having the coating layer <NUM> stacked thereon, and the bottom of <FIG> shows the nucleic acid film <NUM> removed from a mold <NUM>, wherein the coating layer <NUM> and the finishing layer <NUM> are secured to the nucleic acid film <NUM>.

Referring to <FIG> and <FIG>, the nucleic acid film fabrication method according to the third embodiment includes a mixing step (S1), a stirring step (S2), a mixed solution application step (S3), and a drying step (S4).

In addition, the nucleic acid film fabrication method according to the third embodiment may further include at least one of a surface treatment step (S5), a mold preparation step (S6), and a film acquisition step (S7).

With regard to the nucleic acid film fabrication method according to the third embodiment, the same components as those used in the nucleic acid film fabrication method according to the first or second embodiment will be denoted by the same reference numerals as in the first or second embodiment and description thereof will be omitted.

The nucleic acid film fabrication method according to the third embodiment may further include an oblique angle deposition step (S8), a finishing application step (S9) and a finishing drying step (S10).

In the nucleic acid film fabrication method according to the third embodiment, a coating layer <NUM> is stacked on a nucleic acid film <NUM>, followed by stacking a finishing layer <NUM> thereon such that the coating layer <NUM> is embedded between the nucleic acid film <NUM> and the finishing layer <NUM>.

By way of one example, a final product of the nucleic acid film <NUM> may include a microneedle <NUM> or a drug delivery portion <NUM> formed on one surface thereof. Thus, in the oblique angle deposition step (S8), the coating layer <NUM> is formed on the other surface of the nucleic acid film <NUM> such that a portion of the coating layer corresponding to the microneedle <NUM> or the drug delivery portion <NUM> is open. Then, in the finishing application step (S9), a finishing liquid is applied to the other surface of the nucleic acid film <NUM> on which the coating layer <NUM> is formed, and, in the finishing drying step (S10), the finishing liquid applied to the nucleic acid film <NUM> is dried to be formed into a finishing layer <NUM>. In this way, in the film acquisition step (S7), it is possible to obtain the nucleic acid film <NUM> including the coating layer <NUM> and the finishing layer <NUM> integrated therewith.

By way of another example, before the oblique angle deposition step (S8), the nucleic acid film <NUM> may include a microneedle <NUM> extending from one surface thereof toward the human skin and a buffer groove <NUM> formed on the other surface thereof to correspond to the microneedle <NUM> through the mixed solution application step (S3) and the drying step (S4).

Here, the buffer groove <NUM> may be formed using the second mold <NUM>, which is used as the mold <NUM> according to the invention.

In addition, the buffer groove <NUM> may be formed through a process in which, after the mixed solution application step S3 or during the drying step (S4), a groove formation member (not shown) corresponding in shape to the needle groove <NUM>, the buffer formation groove <NUM>, or the delivery groove <NUM> is inserted into the needle groove <NUM>, the buffer formation groove <NUM>, or the delivery groove <NUM>, followed by removal of the groove formation member 10a from the nucleic acid film <NUM> subsequent to the drying step (S4), as shown in the top of <FIG>. Here, depending upon the intended use of the groove formation member 10a, the nucleic acid film <NUM> may be formed with the buffer groove <NUM> and the microneedle <NUM> or may be formed with the drug delivery portion <NUM> having the drug injection hole <NUM> formed therethrough.

After the drying step (S4), in the oblique angle deposition step (S8), the coating layer <NUM> is formed at at least an entrance of the buffer groove <NUM> excluding the bottom end of the buffer groove <NUM>, as shown in <FIG> and <FIG>.

Here, the phrase "excluding the bottom end of the buffer groove <NUM>" means that the bottom end of the buffer groove <NUM> is open, and, more specifically, means that the coating layer <NUM> is formed on the nucleic acid film <NUM> in the following manner: The coating layer <NUM> may be formed only at the entrance of the buffer groove <NUM>, may be formed at the entrance of the buffer groove <NUM> and on a portion of the other surface of the nucleic acid film <NUM> on which the buffer groove <NUM> is formed, or may be formed at the entrance of the buffer groove <NUM> and on the entirety of the other surface of the nucleic acid film <NUM> on which the buffer groove <NUM> is formed.

Although not shown in the drawings, the phase "excluding the bottom end of the buffer groove <NUM>" may mean that the coating layer <NUM> is formed at least on an inner wall of the drug injection hole <NUM> such that the drug injection hole <NUM> can remain open.

Although not shown in the drawings, in the oblique angle deposition step (S8), with the bottom end of the buffer groove <NUM> covered with a separate deposition aid member (not shown), the coating layer <NUM> may be formed at the entrance of the buffer groove <NUM>, followed by removal of the deposition aid member (not shown).

In the oblique angle deposition step (S8), any typical method such as oblique angle deposition, partial plating, partial coating, or sputtering may be employed may be employed to exclude the bottom end of the buffer groove <NUM> from being covered with the coating layer. In the nucleic acid film fabrication method according to the third embodiment, the coating layer <NUM> may be formed by oblique angle deposition. The oblique angle deposition step (S8) includes a process of curing the coating layer <NUM>.

In the finishing application step (S9), a finishing liquid is applied to the mold <NUM> passing through the oblique angle deposition (S8) to fill the buffer groove <NUM> of the nucleic acid film <NUM> while covering the coating layer <NUM>. Here, the finishing liquid is used to form the finishing layer <NUM> and may include the mixed solution set forth above for formation of a nucleic acid film or a mixed solution containing vitamins, collagen and the like for formation of a water-soluble functional film. In addition, the finishing liquid may contain a drug to be absorbed by the human body.

In the finishing drying step (S10), the finishing liquid applied to the mold <NUM> is dried to be transformed into the finishing layer <NUM>. As a result, the finishing layer <NUM> may be formed into a nucleic acid film as set forth above or may be formed into a separate water-soluble functional film.

In this way, in the film acquisition step (S7), a final product of the nucleic acid film <NUM> having the coating layer <NUM> and the finishing layer <NUM> integrated therewith can be obtained. Here, the coating layer <NUM> is embedded between the finishing layer <NUM> and the nucleic acid film <NUM>.

Although not shown in the drawings, the buffer groove <NUM> or the drug delivery portion <NUM> formed with the drug injection hole <NUM> may also be formed on the finishing layer <NUM> by utilizing the method of forming the buffer groove <NUM> on the nucleic acid film <NUM> as described in the third embodiment.

For example, the buffer groove <NUM> or the drug injection hole <NUM> may be formed on the finishing layer <NUM> through a process in which, after the finishing application step (S9) or during the finishing drying step (S10), a groove formation member (not shown) having a different size than the groove formation member inserted into the nucleic acid film <NUM> is inserted into the finishing layer <NUM>, followed by removal of the groove formation member from the finishing layer <NUM> subsequent to the finishing drying step (S10).

Next, a nucleic acid film-based drug administration device according to a first embodiment of the present invention will be described. <FIG> is a sectional view of a nucleic acid film-based drug administration device according to a first embodiment of the present invention. Referring to <FIG>, the nucleic acid film-based drug administration device according to the first embodiment of the present invention includes a nucleic acid film <NUM> fabricated by any one of the nucleic acid film fabrication methods set forth above.

The nucleic acid film-based drug administration device according to the first embodiment includes the nucleic acid film <NUM>, a finishing film <NUM>, and a drug <NUM>.

The nucleic acid film <NUM> is fabricated by any one of the nucleic acid film fabrication methods set forth above and is configured to contact the human skin. Here, the nucleic acid film <NUM> may include the microneedle <NUM> protruding therefrom, wherein the microneedle <NUM> is formed using the mold <NUM> formed with the needle groove <NUM>. The microneedle <NUM> may extend from a surface of the nucleic acid film <NUM> toward the human skin.

Here, the microneedle <NUM> may be reduced in cross-sectional area with increasing distance from the surface of the nucleic acid film <NUM>, that is, may have an inverted conical shape. A maximum diameter of the microneedle <NUM>, that is, a diameter of the base of the microneedle adjoining the surface of the nucleic acid film <NUM> (the diameter of an imaginary circle in which the cross-sectional area of the microneedle <NUM> is inscribed), may range from <NUM> to <NUM>, a diameter of a tip of the microneedle <NUM> may range from <NUM> to <NUM>, and a height of the microneedle <NUM> from the surface of the nucleic acid film <NUM> may range from <NUM> to <NUM>. If the dimensions of the microneedle <NUM> are outside the aforementioned ranges, the microneedle <NUM> can collapse or can be bent with respect to the nucleic acid film <NUM>. Conversely, when the dimensions of the microneedle <NUM> fall within the aforementioned ranges, the nucleic acid film <NUM> can retain a protruding shape thereof, can allow the drug <NUM> to easily penetrate the skin therethrough, can be prevented from being bent or broken when in use, and can be prevented from being broken when separated from the mold <NUM>.

Although not shown in the drawings, the nucleic acid film <NUM> includes the coating layer <NUM> formed thereon such that the tip of the microneedle <NUM> is exposed. Here, the coating layer <NUM> may be formed on the nucleic acid film <NUM> by any one of the nucleic acid film fabrication methods set forth above.

In addition to the coating layer <NUM>, the nucleic acid film <NUM> may further include the finishing layer <NUM> formed thereon. Here, the coating layer <NUM> and the finishing layer <NUM> may be formed on the nucleic acid film <NUM> by any one of the nucleic acid film fabrication methods set forth above.

With the coating layer <NUM>, the strength of the microneedle <NUM> can be reinforced while the microneedle <NUM> can be prevented from being bent or broken.

The finishing film <NUM> is stacked and supported on the nucleic acid film <NUM>. Here, the finishing film <NUM> may be configured in various ways without limitation, so long as the finishing film can prevent degeneration of the drug <NUM>.

The drug <NUM> fills a space between the nucleic acid film <NUM> and the finishing film <NUM>. Here, the drug <NUM> does not decompose the nucleic acid film <NUM>. The drug <NUM> may be comprised of any one selected from therapeutic or health-aid drugs, including drugs for hormone regulation, anesthesia, anti-aging of skin, wrinkle removal, tattoo removal, tattoo formation, and sebum absorption. For example, the drug <NUM> may include hyaluronic acid for anti-aging or wrinkle removal.

When the nucleic acid film <NUM> is attached to the human skin, the drug <NUM> can penetrate the human skin as the nucleic acid film <NUM> is decomposed by moisture remaining on the surface of the nucleic acid film <NUM>, moisture remaining on the human skin, or distilled water or deionized water applied to at least one of the nucleic acid film <NUM> and the human skin.

The nucleic acid film-based drug administration device according to the first embodiment may further include a boundary film <NUM>. The boundary film <NUM> is stacked and supported between the nucleic acid film <NUM> and the finishing film <NUM>. The drug <NUM> fills a space between the nucleic acid film <NUM> and the boundary film <NUM>. In addition, a decomposing liquid <NUM> fills a space between the boundary film <NUM> and the finishing film <NUM>. The decomposing liquid <NUM> may include distilled water or deionized water. Here, the finishing film <NUM> may include a perforation needle <NUM> protruding therefrom and configured to penetrate the boundary film <NUM>.

When the drug administration device is attached to and pressed against the human skin, the decomposing liquid <NUM> is moved toward the drug <NUM> as the perforation needle <NUM> perforates the boundary film <NUM>, such that the nucleic acid film <NUM> can be decomposed by the decomposing liquid <NUM> without separately applying distilled water or deionized water to the nucleic acid film <NUM>, thereby allowing the drug <NUM> to penetrate the human skin.

Next, a nucleic acid film-based drug administration device according to a second embodiment of the present invention will be described. <FIG> is a sectional view of a nucleic acid film-based drug administration device according to a second embodiment of the present invention. Referring to <FIG> and <FIG>, the nucleic acid film-based drug administration device according to the second embodiment of the present invention includes a nucleic acid film <NUM> fabricated by any one of the nucleic acid film fabrication methods set forth above.

The nucleic acid film-based drug administration device according to the second embodiment includes the nucleic acid film <NUM>, a boundary film <NUM>, a finishing film <NUM>, a drug <NUM>, and a decomposing liquid <NUM>.

The nucleic acid film <NUM> is fabricated by any one of the nucleic acid film fabrication methods set forth above and is configured to contact the human skin. The nucleic acid film <NUM> may have the buffer groove <NUM> formed thereon, wherein the buffer groove <NUM> is formed using the mold <NUM> formed with the buffer formation groove <NUM>. The buffer groove <NUM> defines a space for receiving the drug <NUM>. In addition, the nucleic acid film <NUM> may have the microneedle <NUM> protruding from the buffer groove <NUM>, wherein the microneedle <NUM> is formed using the mold formed with the needle groove <NUM>. Here, the buffer groove <NUM> is convex toward the human skin and the microneedle <NUM> extends from the buffer groove <NUM> toward the human skin.

The boundary film <NUM> is stacked and supported on the nucleic acid film <NUM>. Here, the boundary film <NUM> may be configured in various ways without limitation, so long as the boundary film <NUM> can isolate the drug <NUM> from the decomposing liquid <NUM> and can be perforated by a perforation needle <NUM> protruding from the finishing film <NUM>.

Although not shown in the drawings, the nucleic acid film <NUM> includes the coating layer <NUM> formed thereon in such a way that the tip of the microneedle <NUM> is exposed. Here, the coating layer <NUM> may be formed on the nucleic acid film <NUM> by any one of the nucleic acid film fabrication methods set forth above.

The finishing film <NUM> is stacked and supported on the boundary film <NUM>. Here, the finishing film <NUM> may be configured in various ways without limitation, so long as the finishing film can prevent degeneration of the drug <NUM>. The finishing film <NUM> may include a perforation needle <NUM> protruding therefrom and configured to perforate the boundary film <NUM>.

The drug <NUM> fills a space between the nucleic acid film <NUM> and the boundary film <NUM>. Here, the drug <NUM> does not decompose the nucleic acid film <NUM>. The drug <NUM> may be comprised of any one selected from therapeutic or health-aid drugs, including drugs for hormone regulation, anesthesia, anti-aging of skin, wrinkle removal, tattoo removal, tattoo formation, and sebum absorption. For example, the drug <NUM> may include hyaluronic acid for anti-aging or wrinkle removal.

The decomposing liquid <NUM> fills a space between the boundary film <NUM> and the finishing film <NUM>. The decomposing liquid <NUM> may include distilled water or deionized water.

Next, a nucleic acid film-based drug administration device according to a third embodiment of the present invention will be described. <FIG> is a sectional view of a nucleic acid film-based drug administration device according to a third embodiment of the present invention. Referring to <FIG> and <FIG>, the nucleic acid film-based drug administration device according to the third embodiment of the present invention includes a nucleic acid film <NUM> fabricated by any one of the nucleic acid film fabrication methods set forth above.

The nucleic acid film-based drug administration device according to the third embodiment includes the nucleic acid film <NUM>, a boundary film <NUM>, a finishing film <NUM>, a drug <NUM>, and a decomposing liquid <NUM>.

The nucleic acid film <NUM> is fabricated by any one of the nucleic acid film fabrication methods set forth above and is configured to contact the human skin. The nucleic acid film <NUM> may have the drug delivery portion <NUM> protruding therefrom, wherein the drug delivery portion is formed using the mold <NUM> formed with the delivery groove <NUM>. In addition, the nucleic acid film may have the drug injection hole <NUM> passing through the drug delivery portion <NUM>, wherein the drug injection hole <NUM> is formed using the mold formed with the injection protrusion <NUM>. Here, the drug delivery portion <NUM> extends from the nucleic acid film <NUM> toward the human skin and the drug injection hole <NUM> is configured such that leakage of the drug <NUM> therethrough can be prevented due to surface tension of the drug <NUM>.

The boundary film <NUM> is stacked and supported on the nucleic acid film <NUM>. The boundary film <NUM> may be configured in various ways without limitation, so along as the boundary film can isolate the drug <NUM> from the decomposing liquid <NUM> and can be perforated by a perforation needle <NUM> protruding from the finishing film <NUM>.

The finishing film <NUM> is stacked and supported on the boundary film <NUM>. The finishing film <NUM> may be configured in various ways without limitation, so long as the finishing film can prevent degeneration of the drug <NUM>. The finishing film <NUM> has the perforation needle <NUM> protruding therefrom and configured to perforate the boundary film <NUM>.

The nucleic acid film-based drug administration device according to the third embodiment may further include a protective film <NUM> and a separation layer <NUM>.

The protective film <NUM> is detachably coupled to the nucleic acid film <NUM> such that the drug injection hole <NUM> can be open or closed. In addition, the separation layer <NUM> is secured to the protective film <NUM> to be attached to or detached from the nucleic acid film <NUM>. The separation layer <NUM> is configured not to be mixed with the drug <NUM>.

The protective film <NUM> or the separation layer <NUM> further prevents leakage of the drug <NUM> through the drug injection hole <NUM> during transport or storage of the drug administration device while preventing intrusion of foreign matter into the drug injection hole <NUM>.

Next, a nucleic acid film-based drug administration device according to a fourth embodiment of the present invention will be described. <FIG> is a sectional view of a nucleic acid film-based drug administration device according to a fourth embodiment of the present invention. Referring to <FIG> and <FIG>, the nucleic acid film-based drug administration device according to the fourth embodiment includes a nucleic acid film <NUM> fabricated by the method in which the aqueous solution 1a is mixed with the nucleic acid 1b and the drug <NUM>, among the nucleic acid film fabrication methods set forth above.

The nucleic acid film-based drug administration device according to the fourth embodiment includes the nucleic acid film <NUM>. The nucleic acid film <NUM> may be fabricated by the method in which the aqueous solution 1a is mixed with both the nucleic acid 1b and the drug <NUM>, among the nucleic acid film fabrication methods set forth above. Here, the nucleic acid film <NUM> may have the microneedle <NUM> protruding therefrom, wherein the microneedle <NUM> may be formed by the nucleic acid film fabrication method according to the first embodiment of the invention.

The nucleic acid film-based drug administration device according to the fourth embodiment may further include a boundary film <NUM>, a finishing film <NUM>, and a decomposing liquid <NUM>.

Since the boundary film <NUM>, the finishing film <NUM>, and the decomposing liquid <NUM> are the same as those of the drug administration device according to any one of the first to third embodiments, description thereof will be omitted.

According to the nucleic acid film fabrication methods and the nucleic acid film-based drug administration devices set forth above, the nucleic acid film <NUM> is applied to a transdermal delivery technology that relies on drug diffusion across the human skin, thereby improving penetration of the drug <NUM> into the skin while preventing skin problems. In addition, the microneedle <NUM>, the buffer groove <NUM>, and the drug delivery portion <NUM> having the drug injection hole <NUM> formed therethrough can be easily formed on the nucleic acid film <NUM> and the nucleic acid film <NUM> can have a uniform thickness.

Further, according to the present invention, it is possible to prevent intrusion of foreign matter into the nucleic acid film <NUM> while improving decomposition of the nucleic acid film <NUM>. Moreover, the decomposing liquid <NUM> can be stably supplied to the nucleic acid film <NUM>, thereby enabling stable delivery of the drug <NUM>. Furthermore, depending on the form of delivery of the drug <NUM>, the nucleic acid film can be patterned in various ways and the dosage of the drug <NUM> can be adjusted according to the pattern of the nucleic acid film.

In addition, according to the present invention, leakage of the drug <NUM> through the drug injection hole <NUM> and intrusion of foreign matter into the drug <NUM> can be prevented while protecting the nucleic acid film <NUM>.

Although some embodiments have been described herein, it should be understood that these embodiments are provided for illustration only and are not to be construed in any way as limiting the present invention, and that various modifications, changes, alterations, and equivalent embodiments can be made by those skilled in the art without departing from the spirit and scope of the invention.

Claim 1:
A nucleic acid film fabrication method, comprising:
a mixing step (S1) in which <NUM> parts by weight to <NUM> parts by weight of a nucleic acid (1b) is added in powder form to <NUM> parts by weight of distilled water or deionized water (1a) to prepare a mixed solution;
a stirring step (S2) in which the mixed solution is stirred;
a mixed solution application step (S3) in which the mixed solution is applied to a mold (<NUM>) corresponding in shape to a final product of a nucleic acid film (<NUM>);
a drying step (S4) in which the mixed solution applied to the mold (<NUM>) is dried to be formed into the nucleic acid film (<NUM>); and
a film acquisition step (S7) in which the nucleic acid film (<NUM>) is separated from the mold (<NUM>) after the drying step (S4).